I
The startup develops oncology drugs that utilize a potent inhibitor to prevent the repair of DNA single-strand breaks, leading to synthetic lethality in cancer cells. This approach targets multiple solid tumors as a monotherapy and in combination with other anti-cancer agents, addressing the need for more effective cancer treatments.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops oncology drugs that utilize a potent inhibitor to prevent the repair of DNA single-strand breaks, leading to synthetic lethality in cancer cells. This approach targets multiple solid tumors as a monotherapy and in combination with other anti-cancer agents, addressing the need for more effective cancer treatments.